What question did this study set out to answer?

This research aims to understand how anticholinergic burden influences frailty in people with HIV, especially among older adults and those with a history of AIDS.

February 25, 2026

Anticholinergic burden interacts with age and AIDS history to amplify frailty in people with HIV

Key Points

This research aims to understand how anticholinergic burden influences frailty in people with HIV, especially among older adults and those with a history of AIDS.
Analyzed the impact of anticholinergic burden on frailty in individuals with HIV.
Examined the effects of age and history of AIDS on this relationship.
Identified potential strategies for routine assessment and deprescribing.
Anticholinergic burden is linked to increased frailty levels in people with HIV.
Older individuals and those with severe immunosuppression exhibit heightened frailty linked to anticholinergic burden.
Proposed routine assessment can potentially mitigate these effects through deprescribing.

Abstract

ACB is a modifiable contributor to frailty in people with HIV, with disproportionate impact on older individuals and those with prior severe immunosuppression. Incorporating routine ACB assessment and deprescribing strategies into HIV care may help support functional ageing and reduce vulnerability.

AI에게 질문

Bookmark